Overview

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL).
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Hospital, China
Treatments:
Azacitidine
Cyclophosphamide
Decitabine
Doxorubicin
Liposomal doxorubicin
Prednisone
Vincristine